tradingkey.logo
tradingkey.logo
Pesquisar

NewcelX Ord Shs

NCEL
Adicionar à lista de desejos
2.610USD
-0.080-2.97%
Fechamento 11-13 16:00(ET)
14.04MValor de mercado
0.00P/L TTM

Sobre o NewcelX Ord Shs Empresa

NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

NewcelX Ord Shs Perfil

Código da empresa- -
Nome da Empresa- -
Data de listagem- -
CEO- -
Número de funcionários- -
Tipo de títulos- -
Fim do ano fiscal- -
Endereço- -
Cidade- -
Bolsa de valores- -
País- -
Código postal- -
Telefone- -
Site- -
Código da empresa- -
Data de listagem- -
CEO- -

Executivos da empresa NewcelX Ord Shs

Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+29.59%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%
Mr. Olivier Samuel
Mr. Olivier Samuel
Non-Executive Independent Director
Non-Executive Independent Director
81.82K
--
Mr. Olivier Samuel
Mr. Olivier Samuel
Non-Executive Independent Director
Non-Executive Independent Director
81.82K
--
Mr. Olivier Samuel
Mr. Olivier Samuel
Non-Executive Independent Director
Non-Executive Independent Director
81.82K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Prof. Michel Revel, M.D., Ph.D.
Prof. Michel Revel, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
976.43K
+5.59%
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+29.59%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%
Mr. Ronen Twito, CPA
Mr. Ronen Twito, CPA
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
272.40K
+9.50%

Perguntas frequentes

Quem são os cinco principais acionistas de NewcelX Ord Shs?

Os cinco principais acionistas de NewcelX Ord Shs são: Prof. Michel Revel, M.D., Ph.D.
tradingkey.logo
Aviso de risco: Nosso site e aplicativo móvel fornecem apenas informações gerais sobre determinados produtos de investimento. A Finsights não oferece, e o fornecimento de tais informações não deve ser interpretado como se a Finsights estivesse oferecendo, aconselhamento financeiro ou recomendação para qualquer produto de investimento.
Os produtos de investimento estão sujeitos a riscos significativos, incluindo a possível perda do valor investido e podem não ser adequados para todos. O desempenho passado dos produtos de investimento não é indicativo de seu desempenho futuro.
A Finsights pode permitir que anunciantes ou afiliados realizem, ou forneçam anúncios em nosso site, ou aplicativo móvel, ou em qualquer parte deles e pode ser compensada por eles com base em sua interação com os anúncios.
 © Copyright: FINSIGHTS MEDIA PTE. LTD. Todos os direitos reservados.